Case Report

Transfusion management in a pediatric patient with febrile neutropenia with red blood cell autoantibodies: a case report

Ashish Jain¹*, Sharanya Ramakrishnan¹, Parmatma Prasad Tripathi¹, Rekha Hans¹, Deepak Bansal², Ratti Ram Sharma²

¹Department of Transfusion Medicine, ²Department of Paediatrics, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Received: 22 October 2021
Revised: 14 November 2021
Accepted: 16 November 2021

*Correspondence:
Dr. Ashish Jain,
E-mail: ashishjain16@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Febrile neutropenia is a common complication of chemotherapy especially in hematological malignancies associated with sepsis or severe infection. We report a case where a seven-year-old girl with T-cell acute lymphoblastic leukemia (ALL) developed febrile neutropenia (absolute neutrophil count - ANC <500/µl). Patient developed transient red blood cell (RBC) autoantibodies which interfered with compatibility testing and posed a challenge in donor selection for granulocyte transfusion. Direct antiglobulin test (DAT) and compatibility testing were done by column agglutination technique (CAT) using polyspecific anti-human globulin gel cards. Antibody screen was also done by CAT using 3-cell panel. Granulocyte concentrate was collected from eligible donors after taking an informed consent using a cell separator based on continuous flow principle. The patient’s blood group was AB RhD positive, however, the auto-control was positive (2+), DAT was positive (1+) but the antibody screen was negative. Monospecific DAT revealed the characteristic of antibody to be IgG (2+). The donor for granulocyte harvesting was selected on the basis of adopting a least incompatible donor approach. During her hospital stay she was transfused with four granulocyte concentrates, and other blood components without any adverse events. The patient’s blood culture was sterile on day 33 of hospital stay and subsequently she remained afebrile and finally discharged on day 41 in a hemodynamically stable state. The hemogram was - Hb:10.7g/dl, Total leucocyte count (TLC): 5610/µl, ANC: 4375/µl, PLT: 22000/µl. This case draws a special attention to the importance of serological testing in selection of donor for granulocyte transfusion.

Keywords: Febrile neutropenia, Autoantibodies, Red cell transfusion, Granulocyte transfusion

INTRODUCTION

Patients with hematological malignancies on chemotherapy face the risk of febrile neutropenia (FN) which could be life threatening.¹,² FN can be managed by intravenous broad-spectrum antibiotics. Repeated granulocyte transfusions (GTX) were recommended in severe sepsis especially in neutropenia patient with gram negative infection in a pioneer study.³ In a large multicentric randomized controlled trial (RING trial) subjects with neutropenia (absolute neutrophil count (ANC) <500/µL) and having infection were enrolled and it was found that the success rates for granulocyte and control arms did not differ within any infection type, however, subjects who received an average dose per transfusion of ≥0.6×10⁹ granulocytes/kg tended to have better outcomes.⁴ We report a case where a patient with FN required GTX due to severe sepsis and selection of a compatible granulocyte donor was a challenge due to...
presence of red blood cell (RBC) autoantibodies in the recipient.

**CASE REPORT**

A seven-year-old girl who was a known case of T-cell acute lymphoblastic leukemia (ALL) on consolidation phase therapy presented to the pediatric emergency of our institute with high-grade fever and vomiting. The relevant laboratory investigations during her hospital stay are given in table 1.

Blood grouping (ABO and RhD) was done by tube technique. Direct antiglobulin test (DAT), antibody screen (ABS) (3-cell panel) and compatibility testing were done by column agglutination technique (CAT) (LISS Coomb’s card, Bio-Rad, Switzerland). Granulocyte concentrate (GC) was collected from eligible donors after taking an informed consent using a cell separator (Cobe Spectra, Caridian BCT, Lakewood, CO, USA; Version 7.0, PMN program) by bilateral peripheral vascular access as per the departmental standard operating procedure. Each donor received injection G-CSF (300 µg) and oral dexamethasone (8mg) 12 hours prior to donation.

On the basis of history, examination and laboratory parameters a diagnosis of T-cell ALL on consolidation phase with complicated FN was made, having components of multiple organ dysfunction syndrome and sepsis. As her hemoglobin (Hb) was 6.9 g/dl, a requisition was sent to our department for packed RBC (PRBC). The blood group was found to be AB RhD positive, however, the auto-control was positive (1+ on tube, 2+ by CAT) and DAT was also positive (1+), but the ABS was negative.

| Parameters | Day of hospital stay | 1 | 3 | 5 | 7 | 9 | 18 | 22 | 31 | 33 | 35 | 37 | 39 | 41 |
|------------|----------------------|---|---|---|---|---|----|----|----|----|----|----|----|----|
| Hb (g/dl)  |                      | 6.9 | 9.8 | 7.9 | 7.8 | 10.8 | 13.3 | 12.8 | 13.0 | 13.2 | 13.3 | 12.1 | 11.1 | 10.7 |
| Total leucocyte count (/µl) | 110 | 40 | 20 | 10 | 320 | 250 | 670 | 2290 | 4380 | 7260 | 8900 | 7180 | 5610 |
| Platelet count (x10^9/µl) | 2000 | 29000 | 3000 | 11000 | 23000 | 44000 | 14000 | 21000 | 26000 | 12000 | 23000 | 18000 | 22000 |

| Parameters | GC 1 (Day 21) | GC 2 (Day 23) | GC 3 (Day 25) | GC 4 (Day 27) |
|------------|--------------|--------------|--------------|--------------|
| Hemoglobin (g/dl) | 13.6 | 15 | 14.6 | 14.3 |
| Platelets (x10^9/µl) | 300 | 217 | 201 | 341 |
| Pre-donation WBC count (/µl) | 36,600 | 32400 | 27000 | 33,200 |
| Post-donation WBC count (/µl) | 28,100 | 28,300 | 24000 | 27,500 |
| Volume collected (ml) | 450 | 420 | 416 | 410 |
| Total blood volume processed (ml) | 11000 | 8240 | 8226 | 10004 |
| PMN (final product) yield (x10^10) | 2.6 | 1.14 | 0.75 | 1.3 |
| WBC yield (final product) (x10^10) | 2.9 | 1.7 | 0.90 | 2.0 |
| RBC incompatibility | Weak+ | 1+ | 1+ | Weak+ |
| Any adverse effect (in donor) | Nil | Nil | Nil | Nil |
| GC transfusion | Uneventful | Uneventful | Uneventful | Uneventful |
| Pre-transfusion ANC count (/µl) | 90 | 140 | 190 | 610 |
| Post-transfusion ANC count (/µl) | 800 | 620 | 600 | 2310 |

PMN: polymorphonuclear, WBC: white blood cells, RBC: red blood cells, GC: granulocyte concentrate, ANC: absolute neutrophil count

Monospecific DAT was positive (2+) for IgG. Any drug interference causing a positive DAT was ruled out. She had received multiple PRBC transfusions in last four months with no history of adverse reaction. Of the multiple PRBC units crossmatched, two least incompatible units (wk+ to 1+) were transfused under close monitoring uneventfully. In addition, ABO and RhD identical 10 random donor platelet concentrates, and 4 single donor apheresis platelets were also transfused uneventfully during her course of treatment.
FN in the setting of sepsis is one of the indications for GTx. This is a unique case given the immunohematological presentation and therapeutic challenges posed due to multiple comorbidities. Finding donors for granulocyte donation was itself challenging as the patient’s blood was AB RhD positive which has a low frequency (7.74%) among Indian population. Further, motivating donors for getting CSF injection and relieving their apprehension for long duration procedures was also demanding. We had to adopt selection of a least incompatible donor(s) with respect to RBC compatibility testing, due to autoantibody interference. Only 7 out of the 10 donors screened were found to be least incompatible and were considered for donations, however, 3 of them did not turn up due to their time constraints for the procedure and/or possible apprehension of the procedure. Thus, there needs to be strategy donor recruitment and motivation for granulocyte donors as well. Strauss et al, in a study of collection modalities in GC preparation via apheresis, found that 3 out of 4 respondents emphasized the use of leucocyte antibody screening along with ABO and Rh matched granulocytes. However, in a developing country like India, screening for the presence of anti-HLA and anti-HNA in every donor and recipient is not always a feasible option, due to limited availability of these testing platforms and sometimes because of cost-constraints. GCs would invariably have RBC contamination which is typically ameliorated by RBC sedimenting agents like hydroxyethylstarch. Strauss et al in their study found pervasive use of sedimenting agents across the centers. We avoided use of sedimenting agents owing to donor safety issues. All the GTx were uneventful. There was no correlation between strength of incompatibility and granulocyte increment in recipient after transfusion. The trigger for development of autoantibody in this patient could be due to an antibody targeted against an infectious etiology and having cross reactivity with RBC antigens due to molecular mimicry of the epitope. Strength of this autoantibody was not strong (2+). The autoantibody was detected during a transient phase and was cleared off on further testing later. Most of the literature mentions about development of autoimmune hemolytic anemia (AIHA) in lymphoproliferative disorders especially in chronic lymphocytic leukemia, but there are no reports in the setting of T-cell ALL. We could not establish the diagnosis of AIHA due to confounding factors in the setting of sepsis.

CONCLUSION

Our case highlights the significance of serological testing with respect to donor selection for granulocyte collection in a patient with RBC autoantibodies. Also, the setting of GTx requires an integrated approach between the treating physician and transfusion services for an optimal therapeutic benefit to the patient.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Teofili L, Giovanna C, Blasi R, Orlando N, Fianchi L, Zini G, et al. Dose-dependent effect of granulocyte transfusions in hematological Patients with Febrile Neutropenia. PLoS One. 2016;11(8):e0159569.
2. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low risk subgroup at presentation. Arch Intern Med. 1988;148:2561-8.
3. Graw RG Jr, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med. 1972;287:367-71.
4. Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, Strauss RG, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126;2153-61.
5. Lapierre Y, Rigal D, Adam J, Josef D, Meyer F, Greber S, et al. The gel test: A new way to detect red cell antigen-antibody reactions. Transfusion. 1990;30:109-13.

6. Urdahl SG. Cobe spectra® Apheresis system: Designs, Protocols and Results. Infusionstherapie 1989;16(2):30-43.

7. Agrawal A, Tiwari AK, Mehta N, Bhattacharya P, Wankhede R, Tulsiani S, et al. ABO and Rh (D) group distribution and gene frequency: the first multicentric study in India. Asian J Transfus Sci. 2014;8:121-5.

8. Strauss RG, Klein GH, Leitman FS, Price TH, Lichtiger B, Martinez F, et al. Preparation of granulocyte concentrates by apheresis: Collection modalities in the USA. Vox Sang. 2011;100:426-33.

9. Narvios AB, Reddy V, Lichtiger B. Method of removing incompatible red blood cells from granulocyte components. Transfus Apher Sci. 2006;35:179-80.

10. Sallah S, Wan JY, Hanrahan LR. Future Development of Lymphoproliferative Disorders in Patients with Autoimmune Hemolytic Anemia. Clin Cancer Res. 2001;7:791-4.

Cite this article as: Jain A, Ramakrishnan S, Tripathi PP, Hans R, Bansal D, Sharma RR. Transfusion management in a pediatric patient with febrile neutropenia with red blood cell autoantibodies: a case report. Int J Res Med Sci 2021;9:3696-9.